Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Work begins on bird flu vaccine

05.02.2004


CSIRO Livestock Industries and animal health company, Imugene Limited, have started research work designed to develop a vaccine for chickens at risk of contracting the deadly strain of avian influenza now causing havoc in Asia.



The research team aims to deliver a trial vaccine against the virulent H5N1 strain of the disease, within a matter of months. Once developed, the vaccine could be used to safeguard Australia’s poultry industry.

CSIRO’s Dr Chris Prideaux says that even if development of a vaccine is too late to help control the current outbreak in Asia, it would still be possible for researchers to quickly adapt it to deal with new strains of avian influenza.


"In this way, if we are successful in creating a more effective vaccine, this would then provide a new option for controlling avian influenza outbreaks if and when they arise, either in Australia or overseas," he says.

The research will utilise Imugene’s Adenoviral Vector Delivery System (AVDS) - which originated from CSIRO research - to deliver a small portion of the flu genetic material to poultry to stimulate the birds’ immune response and provide protection from the flu virus.

Imugene’s Managing Director, Dr Warwick Lamb, says the platform AVDS allows a new potential vaccine to be constructed quickly at CSIRO’s Australian Animal Health Laboratory (AAHL) in Geelong - one of the world’s leading animal disease diagnosis and research facilities.

"The CSIRO research team have been working with the AVDS and its use with poultry for over a decade and have relevant experience with chicken viruses," Dr Lamb says.

"Vaccines based on the AVDS only use a portion of the viral structure of the flu virus, making them safer than a live attenuated vaccine approach. With the latter approach, there is some risk that the vaccine could mutate or combine with naturally occurring influenza virus, resulting in potential new strains that are not covered by the existing vaccines. The AVDS vaccine would avoid this problem."

However, because different vaccines are required for each strain of the influenza virus, a new AVDS vaccine would only be effective against the strain of the virus (H5N1) it is designed to target.

ABOUT IMUGENE:

Imugene Limited (ASX Code: IMU) is an Australian biopharmaceutical company specialising in the development and commercialisation of animal health products for production animals (pigs and poultry) and companion (pet) animals.

Imugene’s products safely prevent disease and parasites in animals, reduce or eliminate the use of antibiotics, harmful chemicals and drugs and, in production animals, reduce the level of antibiotic and chemical residue entering the human food chain.

Imugene owns the worldwide rights to the Adenoviral Vector Delivery System for pigs and poultry. Patents have been either granted or are under application in the major pig and poultry markets worldwide.

Imugene’s poultry and pig portfolio is tapping into segments worth US$3 billion of the existing US$8 billion global spend on existing treatments per year. The majority of the existing treatments are chemical and antibiotic solutions that are becoming less effective for disease treatment and productivity enhancement. Compounding the problem of diminishing efficacy, governments and health organisations, internationally, are lobbying and legislating against the use of antibiotics in favour of non-chemical treatments.

More information:

Mr Graham Dowland, Imugene’s Executive Chairman, +61 8 9322 9189
Dr Warwick Lamb, Imugene’s Managing Director, +61 2 9870 7330
Dr Chris Prideaux, CSIRO Livestock Industries, + 61 3 5227 5791

Media assistance:
Emma Homes, CSIRO Livestock Industries, + 61 3 5227 5123, 0409 236 152

Bill Stephens | CSIRO
Further information:
http://www.csiro.au/index.asp?type=mediaRelease&id=primugene
http://www.imugene.com

More articles from Agricultural and Forestry Science:

nachricht Plasma-zapping process could yield trans fat-free soybean oil product
02.12.2016 | Purdue University

nachricht New findings about the deformed wing virus, a major factor in honey bee colony mortality
11.11.2016 | Veterinärmedizinische Universität Wien

All articles from Agricultural and Forestry Science >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

Simple processing technique could cut cost of organic PV and wearable electronics

06.12.2016 | Materials Sciences

3-D printed kidney phantoms aid nuclear medicine dosing calibration

06.12.2016 | Medical Engineering

Robot on demand: Mobile machining of aircraft components with high precision

06.12.2016 | Power and Electrical Engineering

VideoLinks
B2B-VideoLinks
More VideoLinks >>>